Immune map of pancreatic cancer evolution
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
This project will collect blood, tissue, imaging, and clinical data from people with pancreatic cancer, benign pancreatic lesions, and healthy volunteers to try to build an AI-based immune map that can detect and track pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT07034339 on ClinicalTrials.gov |
What this trial studies
The project aims to establish a large, multicenter pancreatic cancer cohort and a standardized clinical biorepository that captures blood, tissue, imaging, and clinical data across disease stages. It will collect paired peripheral (blood) and local (tumor and adjacent tissue) immune samples before and after treatment to characterize temporal and spatial immune changes. Investigators will integrate imaging and clinical information with multimodal immune assays and apply intelligent data-fusion methods to map immune evolution. The effort seeks to identify characteristic immune signatures and to develop an AI model to support earlier and more accurate pancreatic cancer diagnosis and monitoring.
Who should consider this trial
Good fit: Ideal participants are adults with primary pancreatic ductal adenocarcinoma (PDAC), patients with benign pancreatic tumors or IPMN confirmed by imaging/pathology, and healthy volunteers without hepatobiliary-pancreatic disease.
Not a fit: People with autoimmune disease, immunodeficiency, recent cancer therapy, recent blood transfusion, active infection, coagulation disorders, or those on immunosuppressive drugs are excluded and therefore unlikely to be enrolled or to benefit directly from participation.
Why it matters
Potential benefit: If successful, this work could enable earlier, more accurate detection of pancreatic cancer and provide immune biomarkers to better track treatment response.
How similar studies have performed: Previous studies combining tumor immune profiling and AI have shown promising results in other cancers, but comprehensive peripheral-to-local immune mapping specifically for pancreatic cancer remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases * Primary PDAC * Patients with benign pancreatic tumors * IPMN patients diagnosed by pathology/imaging Exclusion Criteria: * Having autoimmune diseases * Accompanied by other malignant tumors * History of tumor treatment (except thyroid cancer and breast cancer, cured for more than 5 years) * Acute infection * History of blood transfusion within the past 6 months, or use of drugs that affect peripheral blood components such as recombinant human erythropoietin and interleukin within 2 weeks * Organ decompensation dysfunction * Immunodeficiency syndrome * Hematological precancerous lesions * Accept immunosuppressive therapy * Diagnosed coagulation disease
Where this trial is running
Hangzhou, Zhejiang
- the First Affliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Yangyang Wang
- Email: 12418635@zju.edu.cn
- Phone: 13957830918
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.